Advances in pediatric pharmacology;Quoi de neuf en pharmacologie pediatrique?

Archives de Pediatrie

Volumn 7, Issue 12, 2000, Pages 1330-1338

  Treluyer J M ^a   Pons, G ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Clinical trials; Pediatrics; Pharmacokinetics; Pharmacology, clinical

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CYTOCHROME P450; IMMUNOSUPPRESSIVE AGENT; NEUROLEPTIC AGENT;

CHILD CARE; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; DRUG LABELING; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG UTILIZATION; HUMAN; LEGAL ASPECT; PRESCRIPTION; REVIEW;

EID: 0033636343     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(00)00152-4     Document Type: Short Survey

References (32)

1. Pharmacokinetic principles in paediatric pharmacology: Proof of differences beyond the neonatal period
2. Prolonged sedation associated with secobarbital in newborn infants receiving ventilatory support
3. The pharmacokinetics of chloramphenicol in the neonate and young infant
4. Pharmacological problems in the management of epilepsy in children
5. Pharmacokinetic observations of phenytoin disposition in the newborn and young infant
6. Late effects of anthracycline therapy in childhood in relation to the function of the heart at rest and under physical stress
7. Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography: Diastolic versus systolic parameters
8. Unlicensed and off label drug use in paediatric wards: Prospective study
9. Use of 'offlabel' and unlicensed drugs in paediatric intensive care unit
10. Unlicensed and off label drug use for paediatric patients. General practitioners prescribe SSRIs to children off label
11. Status of new medicines approved by the european medicines evaluation agency regarding paediatric use
12. Expression of CYP2D6 in developing human liver
13. Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period
14. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: In-vivo/in-vitro correlation and inducibility
15. Delayed ontogenesis of CYPIA2 in the human liver
16. Expression of CYP3A in the human liver - Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth
17. Effects of cisapride on QTc interval in neonates
18. Glucuronidation in humans. Pharmacogenetic and developmental aspects
19. The population approach to pharmacokinetic data analysis: Rationale and standard data analysis methods
20. Experience with NONMEM: Analysis of routine phenytoin clinical pharmacokinetic data
21. Maximum likelihood estimation method for random coefficient regression models
22. Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine
23. Population pharmacokinetic analysis of netilmicin in neonates and infants using a nonparametric method
24. Netilmicin in the neonate : Population pharmacokinetic analysis and dosing recommendations
25. Population pharmacokinetics of caffeine in neonates and young infants
26. Population pharmacokinetics of midazolam in neonates
27. Population pharmacokinetics of intravenous indomethacin in neonates with symptomatic patent ductus arteriosus
28. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach
29. An approach for dose finding of drugs in infants: Sedation by midazolam studied using the continual reassessment method
30. Group sequential clinical trials with triangular continuation regions
31. The triangular test to assess the efficacy of metoclopramide in gastroesophageal reflux